tACS Treatment for Cognitive Impairments in Methamphetamine Addicts | NCT06292156 | Trialant
CompletedInterventionalNot ApplicableUpdated Dec 19, 2025
tACS Treatment for Cognitive Impairments in Methamphetamine Addicts
tACS Treatment for Cognitive Impairments in Methamphetamine Addicts
ClinicalTrials.gov ID
NCT06292156
Lead Sponsor
Beijing HuiLongGuan HospitalOTHER
Overall Status
Completed
Study Type
Interventional
Phase
Not Applicable
Enrollment
68Actual
Last Update Posted
Dec 19, 2025Actual
Start Date
Dec 30, 2023Actual
Primary Completion Date
Dec 30, 2024Actual
Completion Date
Dec 30, 2024Actual
Official Title
tACS Treatment for Cognitive Impairments in Methamphetamine Addicts
Brief Summary
To evaluate the cognitive function of methamphetamine Patients.
Investigate the pathological mechanism of methamphetamine patients from the aspects of EEG and biology;
The investigators investigated the effects of transcranial alternating current stimulation (tACS) on cognitive impairments in methamphetamine patients
Methamphetamine Abuse
Theta treatment group
Sham control group
Ages Eligible for Study
Adult (18-64)
Sexes Eligible for Study
Male
Accepts Healthy Volunteers
Yes
Eligibility Criteria
Inclusion Criteria:
Clinical diagnosis diagnosis of methamphetamine use disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)
None of participants had mixed use of other drugs
None of participants had physical disability
None of participants had acute physical or mental illness, hallucinations, acute withdrawal symptoms
None of participants were receiving any medical treatment